A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

This study is testing a new experimental medicine called BNT326 to see if it can safely help fight advanced solid tumors, either alone or combined with other immune-system boosting treatments. The goal is to find the right dose and see how well it works for people whose cancer has returned or spread and hasn't responded to previous therapies.

This trial is for adults 18 or older who have advanced solid tumors that can be measured on scans and who are still able to perform light daily activities. You must also be in good general health, with liver, kidney, and blood tests showing that your body is strong enough to handle the treatment.

You will receive the study medication under close medical supervision so the team can monitor your safety and see how your body reacts to the treatment. Because this is a research study, you will have regular check-ups, blood tests, and scans to help the doctors understand how the medication is affecting your tumor.

This study is currently recruiting new participants at specific research centers in Phoenix, Arizona; San Francisco, California; and Hartford, Connecticut. You can talk to your doctor or a study coordinator at these locations to see if you meet the specific requirements.